{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:22:00Z","timestamp":1783128120586,"version":"3.54.6"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270183"],"award-info":[{"award-number":["32270183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20338"],"award-info":[{"award-number":["U22A20338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25A20132"],"award-info":[{"award-number":["U25A20132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijid.2026.108758","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:05:21Z","timestamp":1777647921000},"page":"108758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP\/VAP in China: a retrospective real-world multicenter cohort study"],"prefix":"10.1016","volume":"169","author":[{"given":"Huangdu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-918X","authenticated-orcid":false,"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijid.2026.108758_bib0001","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis","volume":"79","author":"Mohd Sazlly Lim","year":"2019","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.ijid.2026.108758_bib0002","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jmii.2023.04.004","article-title":"Mortality and ventilator dependence in critically ill patients with ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"56","author":"Kao","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"issue":"12","key":"10.1016\/j.ijid.2026.108758_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111367","article-title":"Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens","volume":"27","author":"Thacharodi","year":"2024","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.ijid.2026.108758_bib0004","doi-asserted-by":"crossref","first-page":"dlaf134","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas","year":"2025","journal-title":"JAC Antimicrob Resist"},{"issue":"9","key":"10.1016\/j.ijid.2026.108758_bib0005","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/microorganisms13091983","article-title":"Carbapenem-resistant Acinetobacter baumannii: virulence factors, molecular epidemiology, and latest updates in treatment options","volume":"13","author":"Karampatakis","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijid.2026.108758_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.ijid.2026.108758_bib0007","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/Durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ijid.2026.108758_bib0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ijid.2026.108758_bib0009","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijid.2026.108758_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01065-24","article-title":"Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK\/PD","volume":"69","author":"Ji","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijid.2026.108758_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01314-25","article-title":"Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections","volume":"13","author":"Patino","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"4","key":"10.1016\/j.ijid.2026.108758_bib0012","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ijid.2026.108758_bib0013","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jmii.2014.10.006","article-title":"Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia","volume":"49","author":"Liu","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2026.108758_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117666","article-title":"Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing enterobacterales and Acinetobacter baumannii","volume":"181","author":"Garcia","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.ijid.2026.108758_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ijid.2026.108758_bib0016","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii","volume":"56","author":"Scott","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.ijid.2026.108758_bib0017","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14787210.2024.2397663","article-title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by gram-negative pathogens: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"10.1016\/j.ijid.2026.108758_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00565-25","article-title":"Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes","volume":"13","author":"Kunz Coyne","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"9","key":"10.1016\/j.ijid.2026.108758_bib0019","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of eravacycline","volume":"58","author":"McCarthy","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.ijid.2026.108758_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107603","article-title":"Population pharmacokinetics\/pharmacodynamics of eravacycline in patients with complicated intra-abdominal infections and community acquired bacterial pneumonia: support for a fixed-dose treatment regimen","volume":"66","author":"Chen","year":"2025","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.ijid.2026.108758_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"6","key":"10.1016\/j.ijid.2026.108758_bib0022","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs Meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.108758_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2110-5820-1-14","article-title":"Renal and neurological side effects of colistin in critically ill patients","volume":"1","author":"Spapen","year":"2011","journal-title":"Ann Intensive Care"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:00:25Z","timestamp":1783126825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226003930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"alternative-id":["S1201971226003930"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108758","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP\/VAP in China: a retrospective real-world multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108758"}}